The Effect of Increasing Doses of Saw Palmetto Fruit Extract on Serum Prostate Specific Antigen: Analysis of the CAMUS Randomized Trial
Abstract
Purpose:
Saw palmetto extracts are used to treat lower urinary tract symptoms in men despite level I evidence that saw palmetto is ineffective in reducing these lower urinary tract symptoms. We determined whether higher doses of saw palmetto as studied in the CAMUS (Complementary and Alternative Medicine for Urologic Symptoms) trial affect serum prostate specific antigen levels.
Materials and Methods:
The CAMUS trial was a randomized, placebo controlled, double-blind, multicenter, North American trial conducted between June 5, 2008 and October 10, 2012, in which 369 men older than 45 years with an AUA symptom score of 8 to 24 were randomly assigned to placebo or dose escalation of saw palmetto, which consisted of 320 mg for the first 24 weeks, 640 mg for the next 24 weeks and 960 mg for the last 24 weeks of this 72-week trial. Serum prostate specific antigen levels were obtained at baseline and at weeks 24, 48 and 72, and were compared between treatment groups using the pooled t test and Fisher's exact test.
Results:
Serum prostate specific antigen was similar at baseline for the placebo (mean ± SD 1.93 ± 1.59 ng/ml) and saw palmetto groups (2.20 ± 1.95, p = 0.16). Changes in prostate specific antigen during the study were similar, with a mean change in the placebo group of 0.16 ± 1.08 ng/ml and 0.23 ± 0.83 ng/ml in the saw palmetto group (p = 0.50). In addition, no differential effect on serum prostate specific antigen was observed between treatment arms when the groups were stratified by baseline prostate specific antigen.
Conclusions:
Saw palmetto extract does not affect serum prostate specific antigen more than placebo, even at relatively high doses.
References
- 1 : Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol2011; 185: 1793. Link, Google Scholar
- 2 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2387. Crossref, Medline, Google Scholar
- 3 : Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol2008; 179: 2119. Link, Google Scholar
- 4 : Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate1998; 37: 77. Google Scholar
- 5 : Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol2000; 163: 1408. Link, Google Scholar
- 6 : Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia?: Mechanisms of action. J Urol2004; 172: 1792. Link, Google Scholar
- 7 : Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II. Adv Ther2010; 27: 555. Google Scholar
- 8 : Saw palmetto for benign prostatic hyperplasia. N Engl J Med2006; 354: 557. Crossref, Medline, Google Scholar
- 9 : Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA2011; 306: 1344. Google Scholar
- 10 : Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clin Trials2009; 6: 628. Google Scholar
- 11 NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection, Version 1.2011. www.nccn.org. Accessed February 2012. Google Scholar
- 12 : Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology2001; 57: 999. Google Scholar
- 13 : Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology2008; 72: 808. Google Scholar
- 14 : Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate1996; 29: 231. Google Scholar
- 15 : Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology1998; 51: 1003. Google Scholar
- 16 : Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol2000; 163: 1451. Link, Google Scholar
- 17 : The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU Int2004; 94: 338. Google Scholar
- 18 : Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting. World J Urol2005; 23: 253. Google Scholar
- 19 : Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev2009; 2. CD001423. Google Scholar
- 20 : Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report2008; 12: 1. Google Scholar
- 21 : Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate2002; 52: 130. Google Scholar
- 22 : Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev2002; 11: 664. Google Scholar
- 23 : Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer2008; 99: 1743. Google Scholar
- 24 : Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA. Int J Androl2009; 32: 479. Google Scholar
